| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Cdc42 (EC50 = 2 μM)
MLS-573151 targets Cdc42 (cell division cycle 42), a small GTPase involved in the regulation of cell morphology, migration, and cell cycle progression. It inhibits Cdc42 by blocking the binding of GTP to the protein. Its high selectivity makes it a valuable tool for studying the specific role of Cdc42 in various cellular processes. |
|---|---|
| ln Vitro |
MLS-573151 can effectively capture the phagocytic ability of granulosa cells. The fluorescence intensity of slicing beads or slices in hemocytes (as a slicing criterion for slicing efficiency) was considerably reduced in granule cells treated with MLS-573151 (50 μM; 15 min) compared to trays [1].
In vitro, MLS-573151 is a specific inhibitor of Cdc42 with an EC50 of 2 µM. It is cell-permeable, allowing it to be used in live-cell assays. Its selectivity for Cdc42 over other GTPases makes it a superior tool for dissecting Cdc42-mediated signaling pathways. |
| ln Vivo |
In vivo, MLS-573151 can be used to study the role of Cdc42 in animal models. By inhibiting Cdc42, it may affect processes such as cell migration, angiogenesis, and tumor invasion. However, specific in vivo efficacy data for this compound are not detailed in the search results. It is a research tool for studying Cdc42 biology.
|
| Enzyme Assay |
The in vitro binding assay for MLS-573151 measures its ability to inhibit the binding of GTP to Cdc42. This is typically a competitive binding assay using radiolabeled GTP. The compound's EC50 (2 µM) is determined by measuring the inhibition of GTP binding. Alternatively, cell-based assays can measure the inhibition of Cdc42-mediated downstream signaling.
|
| Cell Assay |
In vitro cellular studies are conducted using various cell lines. Cells are treated with MLS-573151, and the effects on Cdc42 activity are measured. This can include assessing changes in cell morphology, migration (wound healing assay), and the activity of downstream effectors (e.g., PAK, WASP) by Western blot analysis of their phosphorylation status.
|
| Animal Protocol |
In vivo animal experiments for MLS-573151 are not detailed in the search results. However, as an inhibitor of Cdc42, it could be used in models of cancer, angiogenesis, or wound healing. Animals would be administered the compound, and the effects on disease progression or specific biological processes would be assessed.
|
| ADME/Pharmacokinetics |
MLS-573151 has a molecular formula of C21H19N3O2S and a molecular weight of 377.46 g/mol. It is soluble in DMSO (20 mg/mL) and DMF (30 mg/mL). It is a crystalline solid. For research, it is typically stored at -20°C. Its purity is ≥98%. It is supplied as a research-grade compound.
|
| Toxicity/Toxicokinetics |
Toxicological data for MLS-573151 are limited to preclinical studies. As a research chemical, it is not intended for human use. Its safety profile would need to be established through comprehensive toxicology studies. Standard laboratory safety precautions should be followed.
|
| References |
|
| Additional Infomation |
MLS-573151 is also known as MLS000573151. It is a potent and selective inhibitor of Cdc42. Its ability to block GTP binding makes it a valuable tool for studying Cdc42 function. It is used in cell biology and cancer research to investigate processes like cell migration, invasion, and cell cycle progression.
|
| Molecular Formula |
C21H19N3O2S
|
|---|---|
| Molecular Weight |
377.45946
|
| Exact Mass |
377.119
|
| CAS # |
10179-57-4
|
| Related CAS # |
10179-57-4
|
| PubChem CID |
2837695
|
| Appearance |
White to off-white solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
596.3±60.0 °C at 760 mmHg
|
| Flash Point |
314.5±32.9 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.669
|
| LogP |
1.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
27
|
| Complexity |
622
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)C2=NN(C3=CC=C(C=C3)S(=O)(=O)N)C(C2)C4=CC=CC=C4
|
| InChi Key |
OPPCVEVPKHRJNY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H19N3O2S/c22-27(25,26)19-13-11-18(12-14-19)24-21(17-9-5-2-6-10-17)15-20(23-24)16-7-3-1-4-8-16/h1-14,21H,15H2,(H2,22,25,26)
|
| Chemical Name |
4-(3,5-diphenyl-3,4-dihydropyrazol-2-yl)benzenesulfonamide
|
| Synonyms |
MLS-573151; MLS000573151
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 75~100 mg/mL (198.7~264.9 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6493 mL | 13.2464 mL | 26.4929 mL | |
| 5 mM | 0.5299 mL | 2.6493 mL | 5.2986 mL | |
| 10 mM | 0.2649 mL | 1.3246 mL | 2.6493 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
